Oncology Update Episode 4 by LucidQuest

2 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
???? Exploring the Latest Breakthroughs in Oncology!
Welcome to this week's edition of Oncology Updates, where we bring you the most significant advancements in cancer treatment and clinical research! In this video, we cover everything from billion-dollar acquisitions to groundbreaking clinical trials and regulatory milestones.

Here’s what’s in the spotlight:

???? GSK completes its $1.15 billion acquisition of IDRx, expanding its oncology pipeline with precision therapies for gastrointestinal stromal tumors.

???? Summit Therapeutics partners with Pfizer to co-develop ivonescimab with antibody-drug conjugates for solid tumors, with clinical trials set to begin by mid-2025.

???? Pyxis Oncology receives FDA Fast Track Designation for PYX-201, targeting Extradomain-B Fibronectin in head and neck cancers.

???? Akeso launches its first ADC clinical trial, enrolling patients for AK138 D1 to advance global cancer treatments.

???? Bristol Myers Squibb’s application for Opdivo plus Yervoy in colorectal cancer is accepted by the FDA, with a decision expected by June 23, 2025.

???? Merck’s KEYTRUDA receives priority review from the FDA as a perioperative treatment for head and neck cancer, based on promising KEYNOTE-689 trial results.

???????? Enhertu secures a positive opinion from the CHMP for HER2-low breast cancer, backed by the DESTINY-Breast06 trial data.

???? Camizestrant shows positive results in HR-positive breast cancer when combined with CDK4/6 inhibitors, as indicated by interim data from the SERENA-6 Phase III trial.

????️ Anixa Biosciences’ breast cancer vaccine gains media attention on Fox News for its potential to prevent breast cancer by targeting alpha-lactalbumin.

???? Evaxion extends its Phase 2 trial for the personalized cancer vaccine EVX-01 to gather three-year data on advanced melanoma.

???? BridgeBio and Helix announce a merger to form a publicly listed biotech company, focusing on therapies targeting the RAS and PI3K alpha pathways, backed by $450 million in funding.

???? Stay Ahead in Oncology Research!

✅ Like, share, and subscribe for weekly updates on oncology breakthroughs.
✅ Visit www.lqventures.com for expert healthcare insights and consulting services.
✅ Contact LucidQuest at [email protected] for strategic guidance on oncology innovations and clinical research.

???? Turn on notifications so you never miss an update!

#OncologyUpdates #CancerResearch #ClinicalTrials #HealthcareInnovation #LucidQuest
Category
Oncology
Be the first to comment

Up Next